Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)

Henry N Ginsberg; Ira J Goldberg

doi:10.1161/ATVBAHA.122.317966

Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)

Arterioscler Thromb Vasc Biol. 2023 Mar;43(3):388-398. doi: 10.1161/ATVBAHA.122.317966. Epub 2022 Dec 29.

Authors

Henry N Ginsberg¹, Ira J Goldberg²

Affiliations

¹ Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University New York (H.N.G.).
² Division of Endocrinology, Diabetes and Metabolism, New York University Grossman School of Medicine, New York (I.J.G.).

Abstract

The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 (apolipoprotein C3) and ANGPTL (angiopoietin-like protein) 3 that reduce circulating triglycerides are poised to enter clinical practice. We will review the biology of how inhibition of these 2 proteins affects circulating lipoproteins as well as the current state of clinical development of monoclonal antibodies, antisense oligonucleotides, and silencing RNAs targeting APOC3 and ANGPTL3.

Keywords: angiopoietin-like protein 3; apolipoprotein C3; cardiovascular disease; dyslipidemia; triglycerides.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Angiopoietin-Like Protein 3*
Angiopoietin-like Proteins / genetics
Apolipoprotein C-III
Dyslipidemias* / drug therapy
Humans
Triglycerides / metabolism

Substances

Angiopoietin-Like Protein 3
Angiopoietin-like Proteins
Apolipoprotein C-III
Triglycerides
ANGPTL3 protein, human

Abstract

Publication types

MeSH terms

Substances

Grants and funding